Coverage of 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Published on Friday, 13 September 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 53nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, September 9-13, 2013.
Highlights of this year's meeting include experimental antiretroviral drugs and treatment strategies, CD4 cell gene therapy, HIV/HCV coinfection, liver transplants for people with HIV, and other sexually transmitted infections.
HIVandHepatitis.com ICAAC 2013 conference section
9/13/13
ICAAC 2013: Raltegravir Safest for HIV+ Patients on Cancer Chemotherapy
- Details
- Category: Cancer/Malignancies
- Published on Friday, 13 September 2013 00:00
- Written by Liz Highleyman
The integrase inhibitor raltegravir (Isentress) may be an optimal choice for many HIV positive people undergoing cancer chemotherapy, as it is highly effective and well-tolerated in this population, according to a poster presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.
ICAAC 2013: CD4 Cell Gene Therapy May Enable Functional Control of HIV Off Treatment
- Details
- Category: Search for a Cure
- Published on Thursday, 12 September 2013 00:00
- Written by Liz Highleyman
Two people whose CD4 T-cells were modified to make them resistant to HIV experienced substantial CD4 cell gains and were able to maintain viral suppression after interruption of antiretroviral therapy (ART), according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.
ICAAC 2013: Many Truvada PrEP Users Are Women and Young People, Survey Finds
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 13 September 2013 00:00
- Written by Gus Cairns
An analysis of nationally representative prescription data revealed that nearly half of people taking tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) are women, according to a poster presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver. The study also found that people using Truvada for HIV prevention were more likely to be under age 25 than those using it for treatment.
ICAAC Underway This Week in Denver
- Details
- Category: HIV Treatment
- Published on Wednesday, 11 September 2013 00:00
- Written by Liz Highleyman
The 53nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) kicked off Tuesday and runs throughout the week in Denver. HIVandHepatitis.com will be on site to cover the latest research on HIV and hepatitis B and C.
Web Design and Development by